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INTRODUCTION AND PUP..POSE 
Iron deficiency states are frequently encountered in clinical prac-
tice. All aspects of the situation have been studied for years. Never-
. theless, even some of the fundamental knowledge about iron metabolism 
. . th t ·o,aot. 1,2 '!.T~th is in dispute or has undergone revunon in • e recen _ '" rv ..... 
such a fluctuating body of knowledge, it is not difficult to understand 
why the crnrunercial market has been flooded with a variety of iron prepar-
at ions each purporting to have advantages either in efficacy or' in a lower 
incidence of toxicity. The purpOIBEl of this paper, after a brief review 
of iron metabolism ana history of iron therapy, is to present a more 
detailed analysis of one of the most interesting prepqrations---Iron-
Dextran (Imferon)R. 
IRON HETABOLISt1 
A comprehensive review of the many facets of iron metabolism will 
not be attempted here. Many excellent reviews and books on the subject 
have been published in the recent past. 1,2,3,4,$ 
Certain disorders can cause pathological changes in ferrokinetics 
and iron storage, i.e., pulmonary hemosiderosis, intravascular hemolysis, 
Laennec's cirrhosis., etc., without affecting total body iron content to 
any &,Teat extent. 1 However, the most frequently encountered abnormali-
ties related to iron metabolism are related to either an excess or deti-
ciency of total body iron. Thus, any discussion of iron metabolism must 
focus on factors relating to accUc'nulation ~md excretion of iron by the 
body. (Fig. 1) 
Iron exeretion---
As a metabolit~ iron is somewhat unique in that the excretory route 
is greatly limited. This feature of its metabolism has such important 
implications with regard to the clinical use of iron, particularly 
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parenteral iron, that it will be dealt with first. 
In h~~ns, approximately one-third of body iron excretion occurs 
in the feces and two-thirds is lost from the skin. Very little iron 
is excreted normally in the urine (less than 0.1 mg. per day). Urinary 
iron loss following parenteral iron therapy is of some interest and will 
be discussed later. 
In the past it '-laS felt that t,lle colon could actively excrete excess 
iron. Balance studies as long ago as 1938 indicated that the body has 
no inherent capacity to excrete excess iron into the gastointestinal 
tract. 4 Radioisotope studies indicate that most of the iron found in 
the feces represents only unabsorbed iron from the diet. 4 Total fecal 
iron loss including that from microscopic blood loss and des«iPamated 
intestinal m1.1cosal cells in mormal adult human ,subjects has been calcu-
lated at approximately O.4mg/day. 4 
Total daily iron excretion is not completely fixed. Host cells 
contain iron somewhat in proportion to the quantity of iron in body 
stores. 1 This provides for a lim.i ted selective excretion of iron in 
daily obligatory loss of cells and secretions. F'or example, after 
blood transfusions have caused excessive iron stores, excretion of iron 
exceeds absorption by about 4 mg. per day in an effort to reestablish 
normal body iron equilibrium. 1 
Normal daily excretion in the h'llinan male probably does not exceed 
1 to 2 mg. per day. In the female, where most cases of iron-deficiency 
in this country are encountered, additional losses are incurred through 
menstruation, pregnancy, and ]a cta.tion. In the menstruating female, 
an additional 0.3 to 1 mg. per day is required. r'regnaney demands 
another 2 mg. per day for the duration of gestation and lactation.3 
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The total extra iron loss to the mother is at least 500 lng. attributed 
to the fetus, placenta, and blood loss at delivery. 6,7 
Except for the increased loss of iron in females as noted above, 
the restricted loss of iron from the body is explained by the intra-
cellular location of most of the iron either in tissue stores of incor-
porated in hemoglobin and by the tight chelation by transferrin of that 
small fraction in transit through the plasma. (Fig. 1) 
It is L~portant to know whether parenterally injected iron compounds 
L~fluence the normal excretion of iron. Tnis Will be discussed later. 
Iron absorption---
Iron absorption from the gastrointestinal tract is regulated by 
factors in tr.ree anatomic locations. Intraluminal factors include ana-
t~nic abnormalities, dietary constituents, and intestinal secretions. 1,2,4 
(Table 1) 
Interest in mucosal cell factors has centered around the presence 
or absence of a ltmucosal block" initially proposed by Granick. 8 Accord-
ing to this theory, iron absorption was regulated by an iron-accepting 
protein of the intestinal mucosal cell called apoferritin. However, 
recent '!lOrk causes some objections to this theory • .3 It is now felt 
that iron either in ionic form or in a low molecular weight complex 
crosses the mucosal cell to the vascular border, where it is transferred 
to the plasma by an oxidative process which appears to be the rate lim.i t-
ing reaction. Iron that is not rapidly transferred to plasma is complexed 
with apoferritin to form ferritin, a form of storage iron. In this con-
cept, the apoferritin has no direct regulating affect on iron absorption. 
The third anatomic location exerting some regulatory influence on 
iron absorption from the gut is corporeal with reference especially to 
the demands of erythropoiesis and the tissue iron stores. 
-).+-
The factors regulating iron absorption are very complex and 
our understanding of their interrelationships is somewhat less than 
complete 
Iron transport---
At anyone time there is normally only about 3-4 mg. of iron in 
the plasma. Most of the iron entering the plasma is derived from the 
reticuloendothelial system following breakdown of hemoglobin and the 
major portion leaving the plasma is directed to the bone marrow for 
hemoglobin synthesis. 4,9 Iron released from tissue stores, tissue 
enzymes, and the gut also contributes to the plasma iron pool, although 
to a much lesser extent. In the plasma it is bound to a protein called 
transferrin which is :nade in the liver and has the electrophoretic 
mobility of a Beta-l globulin. 4 It is normally present in the plasTIl2. 
in a concentration sufficient to bind 280-400 meg. of iron per 100 ml. 
of plasma. Normally only one-third of the transferrin is bound to iron. 
Iron storage---
Storage iron in the normal adult comprises about 20-25 per cent of 
the total body iron. Phlebotomy studies by Pritchard revealed tl,:,e aver-
a.ge iron stores in normal adult males to be 819 mg. while those in 
normal nulliparous women were only 254 mg. 10 
During the course of normal pregnancy 'there is an LDcrease in red 
blood cell volume and plasma volume. 6,11 The latter is §,Teater them 
the former so IIhydremia fl develops with a decreased red blood cell count 
and hemoglobin concentration. The majority of workers consider this 
finding as physiological. 6 Others have presented evidence that ade-
quate iron stores 'Ifill almost completely prevent this oecurence. 11 
They point out that the Bantu Negroes in South Africa, who display 
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tissue siderosis resulting from excessive dietary iron, rarely have 
a decrease in hemoglobin concentration during pregnancy. 
Iron stores exist as an intracellular iron-protein complex in 
two different forms. Normally the largest portion is stored as ferritin 
( 60 to 70 per cent ) which is water soluble and cannot be demonstrated 
by staining methods for iron. 2 The rest of the iron is stored as hemo-
siderin which is water insoluble, stainable and thought to be less read-
ily available than ferritin. In cases of microcytic, hypockromie anemias 
examination of marrow for hemosiderin has proved to be a reliable method 
for evaluating iron stores and establishing a diagnosis of iron-deficiency 
anemia. 
Most of the ferritin in the body is located in the reticuloendothe-
lial and parenchymal cells of the liver and spleen. During iron over-
load other parenchymal cells contain significant quantities of iron. 
(This will be discussed further in a later section.) 
Ferrokinetics---
Radioisotopic methods have added sTeatly to our knowledge of iron 
metabolism. Such stUdies have allo;'led us to measure iron turnover rates 
and to appreciate the relative importance and dynamic status of the 
various metabolic circuits. 
The half time of plasma clearance of iron is 60 to 120 minutes and 
the total iron turnover is 20 to 40 mg. per day. 2,3,12 In the normal 
adult male about 21 mg. of iron Der day is utilized and released by 
hemoglobin metabolism. 2 (Fig. 1) Actual human ferrokinetics are more 
complex than is indicated by the brief description above. An integro-
differential mathematical analysis of the data indicates that there are 
both slow and fast components of iron leaving and entering the plasma. 12 
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REVIEttl OF HISTORY OF PARENTERAL IRON Tl'::ERAPY 
The efficacy of oral iron therapy in iron-deficiency anemia 
has been well substantiated in the literature. Most workers have 
found that in the majority of cases the rate of hemoglobin regener-
ation is nearly the same using either oral or parenteral iron prepar-
t · 6,10,13,14 Some k 1:1 h t d t, t th . a l.ons. ... wor ers, . owever, ave repor e 1"la "Joe rl.se 
in hemoglobin after parenteral iron is "double" that of the orally 
treated patients. 15 After the hemoglobin mass has returned to normal 
with oral iron therapy, several more months of continuous iron therapy 
are required to bring about full restoration of the depleted iron stores.10,16 
There are other problems with oral iron therapy. In one study on the 
effects of iron on pregnant women gastrointestinal side effects such as 
constipation, nausea, abdominal pain and diarrhea occured in aL~ost 20 
per cent of patients. 13 However, only about 1 per cent of the patients 
in the above study could not tolerate oral iron in any form. These 
problems with oral iron have led investigators to search for an iron 
preparation suitable for parenteral administration. (Other specific 
indications for parenteral iron therapy will be discussed later.) 
Attempts to supply iron parenterally were made as early as the 
late nineteenth century. Iron citrate and ferrous gluconate were tried 
subcutaneously and intramuscularly. 17 The earliest intravenous prepar-
ations were colloidal ferric hydroxide and colloidal ferric oxide. 16 
All these compounds proved to be too toxic because they liberated iol!P.c 
iron into the plasma too rapidly. The free iron exceeded the iron-
binding capacity of transferrin leading to such toxic symptoms and signs 
B,S a feeling of general warmth, palpitations, flushing of the face, 
engorgement of the neck veins, nausea, vomiting, and even vascular 
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collapse. 17 
The first practical parenteral iron preparation was intro-
duced in 1947. 18 It was a saccharated iron oxide compound admin-
istered intrQvenously. Early studies ~ii th radioiron showed that iron 
injected intravenously is rapidly utilized for hemoglobin production. 19 
However, even 1-rith this substance a significant number of severe toxic 
reactions occurred. 
The search continued for a compound which would complex the ionic 
iron securely enough to prevent toxicity and yet release it readily 
for hemoglobin production. In 1954 a new iron compound was introduced. 20 
It was an iron-dextran complex which was found to be extremely well 
tolerated in mice following large doses either intramuscularly or 
intravenously. 
Since its introduction this preparation has been the subject of 
a great deal of controversy. It was even withdrawn from the market 
for a short tL~e in 1960 following reports that it had a carcinogenic 
potential. 21 
IRON-DEXTRAN (IMFERON)-i1. 
Preparation and chemical properties 2,17 __ _ 
Dextran with molecular weight of 2000 to 20,000 is dissolved with 
anbydrous sodi~~ carbonate in hot water. Ferric chloride is added 
after the solution is cooled. Carbon dioxide is liberated and the 
resultant solution contains colloidal ferric hydroxide ... i th 101AJ mole-
cular weight dextran. After concentration it contains 5 per cent iron 
and has a pH of 5.2 to 6.0. The sodium chloride content is 0.9 per 
cent. The complex is weakly negatively charged, isoto_ic with tissue 
fluid and will not precipitate in plasma over a ve~3 wide pH range. 
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The com:nercial preparation contains 50 mg. of elemental iron per cc. 
Pharrnacology---
1. Absorption 
The route and rate of absorption following intramuscular injection 
depend on the molecular size and local effect of the injected substance. 22 
Substances of molecular weight 20,000 or more are absorbed almost exclu-
sively by the lymphatics while those under 5,000 enter the blood stream 
primarily. Tile average molecular weight of the dextran used in the man-
ufacture of iron-dextran complex is 5,000, but the, final molecular weight 
of the complex is many times this figure. 23 Following Fe59 labelled 
iron-dextran injection, there is no activity or rise in seru.'1l iron for 
4 to 6 hours. 17 However, stainable iron is found in the regional 
lymph nodes within an hour of injection. 22 Thus, it appears that 
iron-dextran is removed from the site of injection by the lymphatic 
system. 
About 80 to 90 per cent of an L~jected dose is absorbed in 48 to 
72 hours with very slow absorption of the remaining matenal. 22,24 In 
rabbits 98 per cent of a large intramuscular dose was absorbed after 
42 days. 24 ~mphatic absorption is dependent upon the rate of lymph 
flow and upon lymphatic capillary permeability both of which are increased 
in an acute inflammatory reaction. Histological stUdies have shown an 
acute inflammatory reaction with degenerative changes in the muscle 
fibers at the site of injection. 22 This inflammatory foeus would be 
expected to enhance absorption of iron-dextran. Within 24 hours tissue 
maerophages begin to appear at the injection site and show a positive 
stain for iron. 22 It is interesting that the na~ber of these iron-
containing macropha,ges remains undiminished for as long as three months. 22 
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It is apparent that iron-dextran uptake by local macrophages makes 
the iron no longer immediately available to the metabolically active 
iron pool. This macrophage uptake explains the slow absorption after 
72 hours. Recent studies using radioiron tagged iron-dextran have 
shown that the last of multiple daily L~jections is consistently better 
absorbed than a single injection. 25 It would appear that the initial 
injection opens up the lymphatic drainage channels so that they are al-
ready working efficiently when subsequent injections are given. 
2. Serum iron 
In cases of acute iron poisoning, shock or coma has been reported 
in 37 per cent of patients whose initial seru~ iron levels were 500 meg. 
per cent or more. 26 In patients treated with daily intra~uscular injec-
tions of 250 mg. of iron-dextran the serum iron content rose to an aver-
age of 1100 to 1200 meg. per 100 mI. on the third to fifth day with no 
evidence of toxic symptoms. 17 This indicates that the iron is not in 
the ionized state but is still complexed with dextran. The iron-binding 
capacity does not decrease, Le., become more saturated with ionized 
iron, until about 72 hours after intrrunuscular injection. The serum 
iron content usually returns to normal values within two to three weeks 
after intramuscular injection. 17 'It is of interest that serum iron 
levels of 104,000 meg. per 100 mI. have been reported following intra-
venous infusion of iron-dextran without toxicity. 27 
3. Urinary excretion 
Due to the high molecular weight of the complex one would not 
expect urinary loss to be significant. Studies with radioiron support 
this assumption in that less than 0.2 per cent of an intravenous dose 
is lost in the urine in the first 72 hours following infusion. 23 High 
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levels of urinary iron excretion have been reported in rabbits follow-
. h' h d f . t l' A t 2.8 :Lng . ~gL4 oses 0 m ra,nlUSCU ar ~on-U.ex roa.n. However, this excre-
tion occured only at doses in excess of 600 mg. Fe per kg. body weight 
and did not occur at dosage levels approxi~atLng those used in clinical 
practice, i.e., about 20 mg. Fe per kg. 
4. :r.1etabolism 
It is evident from the preceding discussion that the iron-dextran 
complex is very stable in the plasma. However, in order for iron to be 
utilized for hemoglobin synthesis it must be in ~~ ionized state. There-
fore, the dextran moiety must be readily split off from the iron in 
order for it to be a~ effective hematinic. The reticuloendothelial 
system would be the logical place for such degradation and, indeed, 
several good studies have confirmed this assumption. 9,23,25,27 As 
discussed previously, the reticuloendothelial system is important in 
internal iron turnover: 
(a) It removes hemoglobLn or non-viable erythrocytes 
from the circulation. 
(b) It splits off the iron from the heme moiety. 
(0) It returns iron to the plasma for transport to 
the marrow. 
(d) It serves as a potential reservoir for storage 
iron. 
Noyes et a19 infused radioiron-tagged erythrocytes into ra~ts and 
humans. They found an almost immediate increase in surface counting 
over the liver and spleen. They found radioiron bound to transferrin 
within thirty minutes after injection of the tagged red cells indicating 
rapid processing by the reticuloendothelial system. Using larger 
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quantities of tagged red cells, they discovered that considerable 
amounts of iron were retained in the reticuloendothelial system for 
twelve days prior to its release into the plasma. 9 Ingestion or 
parenteral injection of iron did not cause an increased release of iron. 
The only stimulus to increase the release of iron from the reticu1o-
endothelial system was a state of increased erytp~opoietie activity. 
I 
Surface counting in more recent studies using radioiron-tagged 
iron-dextran have shown similar increases oyer liver and spleen. 23,25,27 
Following intravenous infusion the tagged complex had a half-life of 
2.5 to 3 days and the plasma was complet~ly cleared in 10 days. 23 It 
should be noted that surface-counting patterns are slluilar after either 
intravenous or intramuscular administration of the complex. 25,27 In 
either case the peak radioactivity is reached about day 7 with. the 
splenic rise being less marked than that of the liver. In anemic sub-
jects, there is a gradual decrease in hepatic and splenic counts over 
the next 14 days. These patterns suggest that the liver and spleen are 
the main initial storage sites of the iron-dextran complex, and that 
the iron is gradually split off to subsequently appear in hemoglobin 
in the circulating erythrocytes. 
There is evidence to suggest that the liver and spleen handle iron 
differently. 9 It is felt that iron is rapidly released by the spleen 
for transport to the marrow, v.rhile liver iron is held in more slmily mov-
ing st~res. It has been found that the plasma clearance of iron-dextran 
is related to the availability of apoferritin needed to form the storage 
compound called ferritin. 23 Studies on the influence of the type of 
iron compound administered on the distribution of storage iron between 
ferritin and hemosiderin revealed some marked differences in distribution. 29 
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Under conditions of iron loading, rabbits receivL~g saccharated iron 
oxide showed a marked increase in hemosiderin deposition while rabbits 
receiving iron-dextran showed a more marked increase in ferritin forma-
tion. This difference in distribution may be the result of differences 
in the rate at which iron is released from the complexes. Saccharated 
iron oxide is cleared from the blood within 24 hours while iron-dextran 
requires 72 hours or more. Perhaps the slower degradation of iron-
dextran allows the liver time to synthesize sufficient apoferritin to 
keep up with the liberated iron. 
Regarding ferritin formation, there is a similarity between iron-
dextran and ferrous sulfate. Both compounds have high magnetic suscep-
tibilities as determLqed by their magnetic moments while saccharated iron 
oxide and ferric hydroxide with slower ferritin production have lower 
magnetic susceptibilities. 29 Further studies are needed to determine 
whether this magnetic state is of significance in the rate of release 
of iron from its carrier or in the rate of its incorporation into the 
ferritin molecule. 
5. Effect on organ system function 
Alznost all the studies done with iron-dextran, both experimental 
and clinical, have measured such parameters of organ function as Bm~, 
standard liver function tests, testicular function tests, etc., and 
have uniformly reported no significant changes in function after iron-
dextran. 25,27,28 A recent study with intravenous iron-dextran investi-
gated the effeet of the therapy on blood-grouping, coagulation, sedimen-
tation, and hemolysis. 16 There was no change in erythrocyte sedimenta-
tion rate, blood coagulation nor was there any significant hemolysis. 
ABO and Rh blood grouping and cross matching were not influenced. 
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Since the pregnant female is frequently found to be iron-deficient, 
it is worthwhile to consider the placental transfer of iron and possible 
effects of iron-dextran therapy on the fetus. Normally the only source 
of fetal iron is the iron circulating in maternal plasma bound to trans-
ferrin. 30 Placental transfer of iron is an active process independent 
of the fetus. Fetectomy in rats does not result in a decrease in pla-
cental uptake of iron. 31 This uptake occurs against a. concentration 
gradient and retrograde transfer from fetus to mother does not occur. 
The amount of iron transported increases markedly as pregnancy pro6Tesses. 
in the rabbit 90 per cent of plasma iron turnover is directed to tho fetus 
at the end of pregnancy. 30,32 No information was found in the litera-
ture on the placental response to circulating iron-dextran. This would 
appear to be an area requiring more investigation. 
Clinical efficacy 
Most investigators report earlier and higher reticulocytosis, but 
similar responses in hematocrit and hemoglobin concentration in compro'-
ing oral with parenteral iron therapy. i{- Reticulocytosis may sta.rt as 
early as the third day and reach a peak at 5 to 10 days of 10 to 15 
per cent. 15 1rlith oral therapy the mean peak value is about one-half 
the above value and is not reached until 6 to 16 days following insti-
tution of therapy. The magnitude of response to iron therapy usually 
reported is summarized in Table 2. It should be mentinned that the rate 
of response depends on the severity of the anemia. In severe aneNia 
the rate of response may exceed 2 gm per cent per week. 15 In one study 
of 75 anemic vIOm8n treated with iron-dextran as a total dose intravenous 
infusion, 30 cases shm.red a rise in the hemoglobin value of 1 to 2 gIll 
i-.1?eferences: 7, 14, 15, 16, 17, 33, 34, 35, 36, 37, 38 
... 14-
per cent v-n thin 48 hours. (The average hemoglobin rise in this study 
was 1 gIn per cent per week. )36 This early rise, although unexpected, 
is possible since stainable iron is present in the marrow at 12 hours 
after infusion. 39 
1. Methods of administration 
At the present time the manufacturer of iron-dextran recommends that 
in the United States it be ad.rninistered only via the int,ramuscular route. 
l{any formulas for determining dosage have been suggested, all based on 
hemoglobin deficit, body weight and status of iron stores. Probably the 
easiest rule to remember is as follows: 250 mg of iron (5 ml of iron-
dextran solution) for each gram per cent of hemoglobin deficiency. 17 
Dosages greater than 5 ml in each buttock per day result in appreciable 
muscle soreness. To prevent brovm staining of the skin at the site of 
Lnjection, a Z-track technique with a two or three inch needle is used. 
It should be remembered that 20 to 25 per cent of an intramuscular dose 
is not readily available for hemoglobin production because of poor 
absorption after the first 72 hours. 
There are certain disadva,ntages to the intramuscuh.r administration 
of iron-dextran that make the intravenous route more appealing such as: 
(1) patients tire of having repeated painful injections, (2) difficulty 
of administration in asthenic patients with little muscle mass, (3) poss-
ibility of brown stainingef the sldn,and (4) rare patients with idio-
pathic thrombocytopenic purpura or other bleedL~g disorders who luay have 
severe tissue bleeding after intramuscular injections. Therefore, the 
total dose infusion technique vIas introduced in 1963. 40 Actually the 
complex Il\l'aS found to be the least toxic of all iron preparations 1.fhen 
given intr<l.venously to animals as early as 1955. 24,38 The LD50 following 
-15-
intravenous infusion in mice is over 1,000 mg of iron per kg body 
weight. 46 Basu40 reported that work in laboratory animals has shown 
tha,t iron-dextran complex, in company \vith physiological iron such as 
ferritin, has a powerful general adrenolytic effect, causing hy;,ooten-
sion, when introduced rapidly into the blood, but this effect does not 
appear 'fihen the complex is diluted and given slowly. Maryhasin and 
Wallerstein39 have used undiluted iron-dextran intravenously in doses 
up to 3000 mg LD 45 patients. No serious untoward effects were observed 
in this study. One patient developed chills and mild abdominal cramps 
8 hours after injection. However, :nost investigators have chosen to 
a&ninister the iron-dextran diluted in 5 per cent glucose or normal 
saline in various concentrations, usually about 10 to 25 ml diluted to 
500 cc. 16,23,27,36,38,40,41 l10st investigators report a hemoglobin rise 
of 1 to 2 gm per cent per week which is comparable with results in suc-
cessful oral~ntramuscular therapy. In order to prevent severe reactions 
certain precautions need to be taken into consideration before selecting 
patients for this form of therapy. 
(a) Patients with cardiac disease should be excluded 
to prevent overloading the circulation and cardiac failure. 
(b) It has been found that patients 'flith active pulmonary 
disease have a higher incidence of bronchospasm after the 
intravenous admL~istration of iron. 
(c) Severe reactions have been reported in cases of 
toxemia of pregnancy 'irith albu!tlL~uria so that patients 'l"lith 
uncon'crolled toxemia and kidney disease should be excluded. 
(d) Severe retl,ctions have also been reported if intra-
venous or intramuscular iron-dextran is folloi'led 10 to 20 
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days later \-vi th a massive intravenous infusion. 
(e) Normal saline has been reported to be better 
tolerated than 5 per cent glucose for the infusion of 
36 iron-dextran complex. 
(f) Most workers suggest using a test dose by 
ri.mning the infusion very slowly for the first fe1rT minutes. 
If the patient complains of giddiness, chest pain, cough, 
or any other discomfort the infusion is discontinued. 
2. Indications for parenteral iron 
For the great majority of cases of iron-deficiency anemia, parent-
eral iron offers no advantages over oral iron therapy. However there 
are certaLn valid indications for parenteral iron and these should be 
enmr.rnerated. 
(a) l1alabsor;?tion of iron from the gastrointestinal 
t:cact as in: 
(1) Total or SUbtotal gastrectomy 
(2) Intestinal disease such as sprue 
(3) Steatorrhea 
(b) Proved intolerance to oral iron. 
(c) Inability to be sure that oral medication is 
taken as in: 
(1) I~~ates of institutions 
(2) Children 
(3) Patients from low socio-economic groups 
(4) Geriatric patients 
(d) Selected chronic hemorrhagic states such as 
congenital telangiectasia.42 
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Adverse effects and toxicity 
The a.dverse effects in 60 patients treated l"i th intramuscular 
iron are sThl1Illarized as follows: 34 
NlL"'!1ber of 
Patients COI!l"nent 
Local discomfort------------All-----------------Rarely lasted more than 
10 to lS minutes 
Pain radiating down 
back of leg---------------3------------------Not likely due to sciatic 
nerve irritation, may be 
related to volwne of intra-
muscular injection 
Brown staining of skin-------5------------------Hinimized by using Z-track 
tec11l1ique d-o.ring injection 
Episode of giddiness 
and malaise for 1 hour 
after injection-----------l------------------The hematocrit in this 
patient was only 15 
Dyspnea, paresthesias, 
and epigastric pain occur-
ing 24 hours after injection--l-----------------Nay have represented anxi-
ety and effects of severe 
anemia 
Occa.sional transient allergic reactions have been reported such as 
urtic('U'ia, arthralgia., lJrmphadenopathy, nausea, vomiting, headache and 
fever. 43,44,45,46,h7 These reactions usually respond well to supportive 
medication and antihistamines. An interesting finding ,-vas reported by 
BovJrnan35 in anemic children treated 1tJith intramuscular iron-dextrcm. 
In tr~ee patients with severely depressed hemoglobin levels (1.9 to 2.6 
gIn per cent), iron-dextran thera.py resulted in a leukoerythroblastic 
response as noted on periphera.l smear. The granulocytic leukccytosis 
was not unlike that of chronic granulocytic leukemia \-li th band forms, 
meta.'Uyelocytes, myelocytes, occasional progranulocytes and rare myeloblasts 
appearing on peripheral smear. These responses t-rere transient and 
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disappeared by the fourteenth day_ 
Studies of acute and chronic toxicity in ani.'11als have shown iron-
dextran to be the least toxic of all the iron preparations. Acute 
toxicity findings were mentioned previously. In determining the chronic 
toxicity of the preparation, Juice, rats, and guinea-pigs have been given 
total doses of more -than 30 times the usual clinical dose and, more than 
a year later, have Sh01fv'TI no ill-effects whatsoever e 24,38 In antigeni-
ci,ty studies, there were no signs of al1aphylaxis in guinea-pigs when 
the challenging dose was ac1llinistered 14 days after sensitization \..rith 
iron-dextran. 24 In the salle report no serurrl antibodies were produced 
in rabbits "'"lhich would react ,·lith either dextran or iron-dextran. 24 
Karlefors and ~Jorden17 found that reactions were most COiTh'110n on 
the fourth day after the initial intramuscular injection. Since skin 
tests with iron-dextran were negative and complement fixation studies 
and precipitin reactions were equivocal, they felt that the theory of 
a sensi tiz ing mechanism could not be supported. It was their opinion 
that most of the reactions ,iere due to the toxic effect of ionic iron 
split off in the reticuloendothelial system. 
Severe reactions and even several deaths following iron-dextran 
therapy have been reported. 43,44,45,46,47 Tne more disturbing 
reactions include headache, vomiting, and fever17, recurrent arthralgia 
and cellulitis43 , transient shock-like conditions44, fever with painful 
enlargement of the inguinal l~oh nOdes45 , encephalopathy46, joint 
effusion46, and one case of cerebral hemorrhage leading to death. 46 
The cause of death was "ventricular hemorrhage most probably due to 
acute h~vpertension resulting from the toxic effects of iron on the 
kidney." 46 Iron was deposited in the endothelial lining of the 
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capillary loops of almost all the glomeruli. Under conditions of 
iron loading with iron-dextran, rabbits died vrith kidney findings simi-
lar to the case above. 28 One study showed that reactions i-iere more 
common in pregnant irwmen th:m in the non-pregnant. 46 They also found 
that reactions were more common and severe 1{hen the anemia was dimorphic 
and when pre-ec1runpsia was present. The incidence of reactions did not 
seem to bear any relationship to the severity of anemia, the dosage of 
iron-dextran, and the serum protein level. It would seem likely that 
some of the reactions reported are allergic in nature Ci!' due to some hyper-
sensitivity, but proof awaits further investigation. 
Intensive and prolonged adLunistration of iron parenterally in 
ani~als results in siderosis of the liver, spleen, inguinal lYMPh nodes, 
and occasionally of lymph nodes elset-There. 28 This vIas not accompanied 
by any detectable disturbance of liver function. Severe iron overload 
by itself does not appear to induce tissue damage. 48 However, studies 
on ~on-induced liver damage support the conclusion that a liver loaded 
;'7i th iron is more vulnerable to the action of toxic agents or deficient 
diets. 48,49,50,51 After 40 weeks of iron-dextran injections in monkeys 
the liver was found to contain much iron in macropha.ges and also in 
parenchymal cells, but no histological evidence of cirrhosis or of any 
pre-cirrhotic changes was observed. 52 
Carcinogenic potential 
In 1959, Rich~ond53 reported sarcoma production at the site of injec-
tion of iron-dextran in rats. This effect has been well substantiated 
by others in mice and rats and is now undisputed. 21 However, most of 
these studies have been done loii th larger doses than those used clinically 
in relation to body weight. In 1960, Robinson et a154 reported a hmnan 
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case of possible association of malignant neoplasm with iron-dextran 
injection. Four years after a short series of iron-dextran injections 
in the left deltoid area of a 7L~ year old 'VJhite female, a, soft mass ,"las 
noted. The initial pathological diagnosis ltVas undifferentiated sarcoma. 
There was a :narked difference in the histologic appearance of the tumor 
and those produced in rats. Since that tL~e slides of this tumor have 
been sent to many pathologists in the U.S.A. and Canada. There was 
a great deal of variation of opinion as to the type of tumor although 
the Llajority agreed that it was malignant. 47 Roe and Carter55 tested 
the assulllption that sarcomas were produced only at very high doses. 
They found sarcomas at the site of injection in 8 out of 16 rats receiv-
ing 16 injections of 0.75 mlof iron-dextran at weekly intervals. In 
128 rats receiving 2 injections of 0.75 ml of iron-dextran only 5 
sarcomas were found. The most malignant tumors were found in ani..'1lals 
receiving the highest doses. It should be pointed out that the animals 
on the lowest dosages received an amount equal to 375 mg per kg body 
weight which is still considerably more than the average clinical dose 
of 2') mg per kg. The majority of tUt'llors appeared only after 400 to 
600 days follmving injections. It has been suggested that the latent 
period before the appearance of iron-dextran sarcomas may be as long as 
one-quarter to one-third of the life-span of the species in question. 52 
Monkeys failed to develop tumors after as many as 40 weekly injections 
of 0.25 ml iron-dextran. They \vere observed for as long as a year, but 
this period of observation may still have been too short. In view of 
the long latent period between exposure to iron-dextran and the appear-
ance of sarcomas we may have to wait 15 to 20 years for a useful answer 
to the question of possible carcinogenic effect of iron-dextran in man. 
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S~~ary and conclusions 
After a brief review of iron metabolism including information 
from some of the, newer ferrokinetic studies, the physiologic and 
pharmacoloisic effects of iron-dextran \,rere discussed. It would 
appear that in the majority of cases of iron deficiency oral iron 
therapy is indicated because of the possible adverse effects and toxic 
reactions from iron-dextran. Most investigators report similar clinical 
responses with oral or parenteral iron therapy. Specific indications 
for parenteral iron therapy were discussed. 
Iron deficiency in the United Ste.tes is probably [!lost C0111110n in 
pregnant women. A higher incidence of toxic reactions following iron-
dextran therapy has been reported in pregnant than in non-pregnant 
-vwmen. Very little information is available on the effects of iron-
dextran on the fetus and placenta. Since considerable nm!lbers of 
pregnant i<lOmen are receiving iron-dextran, studies on placental 
transfer of this substance should be done. 
The total dose infusion technique introduced recently offers 
several advantages over intramuscular injections. Since the reported 
incidence of reactions seems to be no greater with this method, it 
deserves further investigation. 
A great variety of reactions to iron-dextran have been reported. 
Some of these reactions are undoubtedly due to the toxic effect of 
ionic iron split off too rapidly by the reticuloendothelial system. 
Others seem to ha.ve an allergic or hypersensitivity basis. Further stu-
dies in this area seem indicated. 
The question of possible carcinogenic effect of iron-dextran in 
man is unresolved. Since the latent period may be as long as one-third 
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of the life span of the species, we may have to wait 15 to 20 
years for a useful answer. 
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Figure 1: Iron Hetabolism 
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,~ 
(R.E. System) 
20 mg daily 
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) 
.. 
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1000 mg 
\ 
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2500 mg 
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daily 
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" 
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. 11yoglobin 
Resp. Enzymes 
300 mg 
From. Conrad, 11. E.: Maryland Med. J., 
17:76, 1968. 
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Table 1 
Intraluminal Factors 
Increase Absorption Decrease Absorption 
DIET/I....,'tY 
1. Precipitatin« chelates 
a. carbtnate X 
b. phos hate X 
c. Phlate X d. oxa ate X 
2. Sugars X 
3. Amino tids . X 
4. X Other ldUCiUg substances 
e.g. Ascorbic acid 
GASTRIC 
I 
I 
1. HCl I X I 
I 
2. IntrinlC factor X 
3. Gastrof rrin X 
I 
BILE 
1. Ascorba e X 
2. Glutath ione X 
PftJICREAS 
1. Bicarb nate X 
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Table 2 
Response to Iron Therapy 
IRON PREPARATION 
I..l1tramuscular: 
1. Iron-Dextran 
2. Iron-Sorbitex 
Oral: 
DOSE 
(mg~ 
250 
100 
3. Ferrous Sulfate 180 
4. F'errous Gluconate 220 
5. Ferrous Fumarate 200 
NO. OF 
SUBJECTS 
11 
10 
10 
8 
INITIAL 
HEHOGLOBIN 
(gm of'l • /01 
INCRE..4.SE 
PER 
D..ltY 
(gm %) 
0.28 
0.26 
0.25 
0.25 
0.26 
From Scott, D. E. et al: Obstet. Gynec. 
30:679, 1967. 
TOTAL 
HEI10GlOBIN 
PRODUCTION 
eX NORlvIAL} 
2.9 
2.8 
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